Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance, Compliance, & Regulatory Information

Guidance, Compliance, & Regulatory Information

                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          Notice to Industry:  Postmarketing Requirements  - Postmarket studies and clinical trialsGuidance, Compliance, & Regulatory Information Notice to Industry:  Postmarketing Requirements  - Postmarket studies and clinical trials
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFDA’s mission is to ensure that safe and effective new drugs are available as quickly as possible and that drugs already marketed remain safe and of the highest quality for as long as the drugs remain on the U.S. market.As part of this authority, industry should be on notice that FDA intends to vigorously enforce requirements that sponsors conduct postmarket studies and clinical trials.In 2007, Congress passed the Food and Drug Administration Amendments Act of 2007 (FDAAA), which amended the Food, Drug, and Cosmetic Act (the Act) to provide the agency with substantial new authorities to ensure the safe and appropriate use of drugs.One of these provisions gives FDA the authority to require drug companies to conduct postmarketing studies or clinical trials – known as postmarketing requirements (PMRs).FDA may require these PMRs either at the time of approval or after approval if the agency becomes aware of new safety information that could indicate a serious potential risk associated with the use of the drug (section 505(o)(3) of the Act).FDA may require postmarketing studies and clinical trials:To assess a known serious risk related to the use of the drug;To assess signals of a serious risk related to the use of the drug; andTo identify an unexpected serious risk when available data indicate the potential for serious risk.Once FDA notifies a drug sponsor of the need for a postmarketing study or clinical trial, the company is required to provide a timetable for completion, including study milestones, and periodic status reports on progress toward completion of the PMRs.If a company fails to comply with the timetable, FDA is authorized to take enforcement action against the company, unless the company can demonstrate good cause for the failures.FDA’s enforcement actions may include issuing a Warning Letter and assessing civil monetary penalties. A company that violates postmarketing study requirements may be subject to civil monetary penalties of up to $250,000 per violation, with the possibility of additional monetary penalties if the violation continues uncorrected.In addition, if a company violates postmarketing study requirements, its product may be deemed misbranded.Reflecting the agency’s commitment to enforce these statutory provisions, FDA intends to take enforcement action against companies that fail to conduct these required studies in a timely manner.Guidance for Industry:  Postmarketing Studies and Clinical Trials – Implementation of Section 505(o)(3)of the Federal Food, Drug, and Cosmetic Act (Drug Safety, April 2011) [PDF - 276KB]

                                                                                  Content current as of:
      02/12/2016Guidance, Compliance, & Regulatory Information

          
                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop